Histidine and Carnosine Alleviated Hepatic Steatosis in Mice Consumed High Saturated Fat Diet
Overview
Authors
Affiliations
The effects of histidine, alanine and carnosine on activity and/or mRNA expression of lipogenic enzymes and sterol regulatory element-binding proteins (SREBPs) in liver and adipose tissue from high fat diet treated mice were examined. Histidine, alanine or carnosine, each agent at 1g/l was added into drinking water for 8-wk supplement. Histidine or carnosine supplement increased hepatic levels of alanine, histidine and carnosine. High fat diet evoked lipogenesis via raising the activity and mRNA expression of glucose-6-phosphate dehydrogenase, malic enzyme, fatty acid synthase (FAS), 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, SREBP-1a, -1c and -2 in liver and adipose tissue (P<0.05), which consequently increased mice body weight, epididymal fat, and hepatic triglyceride and cholesterol contents (P<0.05). The intake of histidine or carnosine significantly diminished the activity and mRNA expression of malic enzyme, FAS, HMG-CoA reductase, SREBP-1c and SREBP-2, which led to lower body weight, epididymal fat, and hepatic triglyceride and cholesterol levels (P<0.05). Mice consumed high fat diet exhibited hyper-insulinemia, hyper-leptinemia, hypo-adiponectinemia and hypo-ghrelinemia. Histidine or carnosine treatments significantly improved insulin sensitivity and attenuated hyper-insulinemia (P<0.05). These results support that histidine and carnosine are effective agents for mitigating high fat diet induced hepatic steatosis.
Infants with biliary atresia exhibit an altered amino acid profile in their newborn screening.
Uecker M, Prehn C, Janzen N, Adamski J, Vieten G, Petersen C Metabolomics. 2024; 20(5):109.
PMID: 39369162 PMC: 11455667. DOI: 10.1007/s11306-024-02175-2.
The inverse associations of glycine and histidine in diet with hyperlipidemia and hypertension.
Rahemi M, Zhang Y, Li Z, Guan D, Li D, Fu H Nutr J. 2024; 23(1):98.
PMID: 39175065 PMC: 11340119. DOI: 10.1186/s12937-024-01005-4.
Quesada-Vazquez S, Castells-Nobau A, Latorre J, Oliveras-Canellas N, Puig-Parnau I, Tejera N Cell Rep Med. 2023; 4(12):101341.
PMID: 38118419 PMC: 10772641. DOI: 10.1016/j.xcrm.2023.101341.
Saadati S, Cameron J, Menon K, Hodge A, Lu Z, de Courten M Nutrients. 2023; 15(22).
PMID: 38004228 PMC: 10674211. DOI: 10.3390/nu15224835.
Yang H, Wei D, Zhang Y, Jian W Endocr Metab Immune Disord Drug Targets. 2023; 24(6):691-708.
PMID: 37859322 DOI: 10.2174/0118715303257018230927182802.